Leukemia Clinical Trial
Official title:
Feasibility of Implementing Yoga Intervention for Adolescents at St. Jude Children's Research Hospital
Verified date | December 2016 |
Source | St. Jude Children's Research Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Researchers at St. Jude Children's Research Hospital want to investigate the feasibility of
a yoga intervention for adolescents receiving treatment for lymphoma or leukemia.
Adolescents who participate in the program may experience improved physical and psychosocial
measures. Improvements in these areas may increase participation in meaningful activity and
improve quality of life.
Adolescents diagnosed with cancer may experience more fatigue, anxiety and pain during
treatment. Yoga is considered a complementary alternative medicine (CAM) that has been
implemented into some pediatric oncology rehabilitation programs and has been shown to be
beneficial in both inpatient and outpatient settings. It may decrease anxiety and increase
quality of life and hamstring flexibility in teens.
PRIMARY OBJECTIVE:
- To determine the feasibility of yoga intervention for adolescents during lymphoma and
leukemia treatment.
OTHER PRE-SPECIFIED OBJECTIVE:
- To obtain pilot data regarding efficacy of yoga on pain, quality of life, fatigue and
physical performance.
Status | Terminated |
Enrollment | 2 |
Est. completion date | December 2016 |
Est. primary completion date | December 2016 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 13 Years to 17 Years |
Eligibility |
Inclusion Criteria: - Patient being treated at St. Jude Children's Research Hospital - Diagnosis of lymphoma or leukemia as documented in medical record - Physician approval to participate in intervention - Ages 13-17 years - Ability to come to standing from seated position without assistance - Parent or legal guardian consent - Adolescent gives assent - English speaking Exclusion Criteria: - Participant not planning on remaining at St Jude for at least 4 weeks - Cognitive impairment that prevents participant from answering questions in standardized assessments |
Country | Name | City | State |
---|---|---|---|
United States | St. Jude Children's Research Hospital | Memphis | Tennessee |
Lead Sponsor | Collaborator |
---|---|
St. Jude Children's Research Hospital |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Mean Change in PedsQL Cancer Module Score | Mean ± standard error will be provided. | Baseline at initial evaluation to follow-up evaluation (up to 6 weeks later) | |
Other | Median Change in PedsQL Cancer Module Score | Median (range) will be provided. | Baseline at initial evaluation to follow-up evaluation (up to 6 weeks later) | |
Other | Mean Change in PedsQL Multidimensional Fatigue Scale | Mean ± standard error will be provided. | Baseline at initial evaluation to follow-up evaluation (up to 6 weeks later) | |
Other | Median Change in PedsQL Multidimensional Fatigue Scale | Median (range) will be provided. | Baseline at initial evaluation to follow-up evaluation (up to 6 weeks later) | |
Other | Mean Change in Quadriceps Strength | The "Biodex System 3 Dynamometer" will be utilized to measure isometric quadriceps muscle contractions. Mean ± standard error will be provided. | Baseline at initial evaluation to follow-up evaluation (up to 6 weeks later) | |
Other | Median Change in Quadriceps Strength | The "Biodex System 3 Dynamometer" will be utilized to measure isometric quadriceps muscle contractions. Median (range) will be provided. | Baseline at initial evaluation to follow-up evaluation (up to 6 weeks later) | |
Other | Mean Change in Grip Strength | A calibrated "Jamar" hydraulic hand dynamometer will be used to measure grip strength. Mean ± standard error will be provided. | Baseline at initial evaluation to follow-up evaluation (up to 6 weeks later) | |
Other | Median Change in Grip Strength | A calibrated "Jamar" hydraulic hand dynamometer will be used to measure grip strength. Median (range) will be provided. | Baseline at initial evaluation to follow-up evaluation (up to 6 weeks later) | |
Other | Mean Change in Hamstring Flexibility | Hamstring flexibility will be assessed by the Sit and Reach Test. Mean ± standard error will be provided. | Baseline at initial evaluation to follow-up evaluation (up to 6 weeks later) | |
Other | Median Change in Hamstring Flexibility | Hamstring flexibility will be assessed by the Sit and Reach Test. Median (range) will be provided. | Baseline at initial evaluation to follow-up evaluation (up to 6 weeks later) | |
Other | Mean Change in Balance | Mean ± standard error on the Bruininks-Oseretsky Test of Motor Proficiency will be provided. | Baseline at initial evaluation to follow-up evaluation (up to 6 weeks later) | |
Other | Median Change in Balance | Median (range) on the Bruininks-Oseretsky Test of Motor Proficiency will be provided. | Baseline at initial evaluation to follow-up evaluation (up to 6 weeks later) | |
Other | Mean Change in Verbal Numeric Pain Scale | Summary statistics of mean ± standard error will be provided. Longitudinal change for the numeric pain scale across the yoga session will be reported. | Baseline at initial evaluation to follow-up evaluation (up to 6 weeks later) | |
Other | Median Change in Verbal Numeric Pain Scale | Summary statistics of mean ± standard error will be provided. Longitudinal change for the numeric pain scale across the yoga session will be reported. | Baseline at initial evaluation to follow-up evaluation (up to 6 weeks later) | |
Primary | Rate of patients who are willing to participate | The rate of participants who are willing to participate on this protocol to the total number of participants approached. It is anticipated that 50% approached patients will agree to participate on the study. Twenty five patients will be approached and asked to participate in the study. If more than 6 patients out of 25 approached patients refuse to participate in the study, the study will be closed, and it will be concluded that the trial is not feasible. | Day 0 | |
Primary | Rate of patients who complete the study | The rate of enrolled and consented patients who complete the 60-minute yoga sessions offered over a 4-6 week period to the total number of participants on the study. It is hypothesized that 60% of those participants will complete the intervention. Thus, if more than 5 patients can not complete the intervention, then it will be concluded that the trial is not feasible. | At end of 4-6 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05691608 -
MoleculAr Profiling for Pediatric and Young Adult Cancer Treatment Stratification 2
|
N/A | |
Recruiting |
NCT04092803 -
Virtual Reality as a Distraction Technique for Performing Lumbar Punctures in Children and Young Adu
|
N/A | |
Active, not recruiting |
NCT02530463 -
Nivolumab and/or Ipilimumab With or Without Azacitidine in Treating Patients With Myelodysplastic Syndrome
|
Phase 2 | |
Completed |
NCT00948064 -
Vorinostat in Combination With Azacitidine in Patients With Newly-Diagnosed Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)
|
Phase 2 | |
Completed |
NCT04474678 -
Quality Improvement Project - "My Logbook! - I Know my Way Around!"; ("Mein Logbuch - Ich Kenne Mich Aus!")
|
N/A | |
Terminated |
NCT00801931 -
Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders
|
Phase 1/Phase 2 | |
Recruiting |
NCT03948529 -
RevErsing Poor GrAft Function With eLtrombopag After allogeneIc Hematopoietic Cell trAnsplantation
|
Phase 2 | |
Completed |
NCT01682226 -
Cord Blood With T-Cell Depleted Haplo-identical Peripheral Blood Stem Cell Transplantation for Hematological Malignancies
|
Phase 2 | |
Completed |
NCT00003270 -
Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer
|
Phase 2 | |
Active, not recruiting |
NCT02723994 -
A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia
|
Phase 2 | |
Terminated |
NCT02469415 -
Pacritinib for Patients With Lower-Risk Myelodysplastic Syndromes (MDS)
|
Phase 2 | |
Recruiting |
NCT04856215 -
90Y-labelled Anti-CD66 ab in Childhood High Risk Leukaemia
|
Phase 2 | |
Recruiting |
NCT06155188 -
Post-transplant PT/FLU+CY Promotes Unrelated Cord Blood Engraftment in Haplo-cord Setting in Childhood Leukemia
|
N/A | |
Completed |
NCT00001637 -
Immunosuppressive Preparation Followed by Blood Cell Transplant for the Treatment of Blood Cancers in Older Adults
|
Phase 2 | |
Active, not recruiting |
NCT04188678 -
Resiliency in Older Adults Undergoing Bone Marrow Transplant
|
N/A | |
Completed |
NCT02910583 -
Ibrutinib Plus Venetoclax in Subjects With Treatment-naive Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma (CLL/SLL)
|
Phase 2 | |
Completed |
NCT01212926 -
Early Detection of Anthracycline Cardiotoxicity by Echocardiographic Analysis of Myocardial Deformation in 2D Strain
|
N/A | |
Terminated |
NCT00014560 -
Antibody Therapy in Treating Patients With Refractory or Relapsed Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia
|
Phase 1 | |
Recruiting |
NCT04977024 -
SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer
|
Phase 2 | |
Recruiting |
NCT05866887 -
Insomnia Prevention in Children With Acute Lymphoblastic Leukemia
|
N/A |